Literature DB >> 29194102

Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use Disorders.

Efrat Aharonovich1, Aimee N C Campbell, Matisyahu Shulman, Mei-Chen Hu, Tiffany Kyle, Theresa Winhusen, Edward V Nunes.   

Abstract

OBJECTIVE: This study is a secondary descriptive analysis that explores and compares the cognitive profiles of adults entering treatment at geographically diverse community-based substance use disorder treatment facilities.
METHODS: Performance on cognitive measures at baseline was compared across 5 primary substance subgroups of individuals (alcohol = 104; cocaine = 102; stimulants = 69; opioids = 108; marijuana = 114) enrolled in a web-based psychosocial treatment study conducted within the National Drug Abuse Treatment Clinical Trials Network. MicroCog subtests were used to assess cognitive domains of attention and mental control, reasoning and cognitive flexibility, and spatial processing.
RESULTS: The average age of onset for a substance use disorder was early to mid-20s, with marijuana users reporting the earliest age of onset (mean 19.9, SD 7.5) and stimulant users reporting the latest (mean 25.2, SD 9.9). Among the total sample, half (49.7%) demonstrated impairment in cognitive flexibility and reasoning, and over one-third (37.3%) had impairment in verbal learning and memory. Stimulant (37.68%) and cocaine (34.31%) users showed significantly greater clinical impairment in attention and mental control compared with alcohol users (17.31%) and opioid (21.30%) users (stimulant subgroup only) (χ [4] = 10.97, P = 0.027). Cocaine users showed the greatest overall impairment across total and proficiency subtest scores, although these were not statistically different from other subgroups.
CONCLUSIONS: These findings confirmed previous studies, indicating a high prevalence of significant cognitive dysfunction across all substance use categories among treatment-seeking adults, and found that cocaine use appears to be associated with the most impairment. Increasing knowledge of similarities and differences between primary substance subgroups can help guide substance use disorder treatment planning.

Entities:  

Mesh:

Year:  2018        PMID: 29194102      PMCID: PMC5931699          DOI: 10.1097/ADM.0000000000000372

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  39 in total

Review 1.  What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?

Authors:  Maria Jose Fernández-Serrano; Miguel Pérez-García; Antonio Verdejo-García
Journal:  Neurosci Biobehav Rev       Date:  2010-05-06       Impact factor: 8.989

2.  Intellectual and neuropsychological functions in young men with heavy and long-term patterns of drug abuse.

Authors:  P Bruhn; N Maage
Journal:  Am J Psychiatry       Date:  1975-04       Impact factor: 18.112

3.  Prefrontal cortical dysfunction in abstinent cocaine abusers.

Authors:  Karen Bolla; Monique Ernst; Kent Kiehl; Maria Mouratidis; Dana Eldreth; Carlo Contoreggi; John Matochik; Varughese Kurian; Jean Cadet; Alane Kimes; Frank Funderburk; Edythe London
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2004       Impact factor: 2.198

4.  Cognitive deficits predict low treatment retention in cocaine dependent patients.

Authors:  Efrat Aharonovich; Deborah S Hasin; Adam C Brooks; Xinhua Liu; Adam Bisaga; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-09-19       Impact factor: 4.492

5.  Neurocognitive deficits in cocaine users: a quantitative review of the evidence.

Authors:  Diana Jovanovski; Suzanne Erb; Konstantine K Zakzanis
Journal:  J Clin Exp Neuropsychol       Date:  2005-02       Impact factor: 2.475

6.  Cognitive barriers to readiness to change in alcohol-dependent patients.

Authors:  Anne-Pascale Le Berre; François Vabret; Céline Cauvin; Karine Pinon; Philippe Allain; Anne-Lise Pitel; Francis Eustache; Hélène Beaunieux
Journal:  Alcohol Clin Exp Res       Date:  2012-03-28       Impact factor: 3.455

Review 7.  Cognitive enhancers in the treatment of substance use disorders: clinical evidence.

Authors:  Kathleen T Brady; Kevin M Gray; Bryan K Tolliver
Journal:  Pharmacol Biochem Behav       Date:  2011-04-29       Impact factor: 3.533

8.  Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.

Authors:  A J Jaffe; B Rounsaville; G Chang; R S Schottenfeld; R E Meyer; S S O'Malley
Journal:  J Consult Clin Psychol       Date:  1996-10

9.  Cognitive deficits in marijuana users: Effects on motivational enhancement therapy plus cognitive behavioral therapy treatment outcome.

Authors:  Efrat Aharonovich; Adam C Brooks; Edward V Nunes; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2008-03-07       Impact factor: 4.492

10.  Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers.

Authors:  T J Ornstein; J L Iddon; A M Baldacchino; B J Sahakian; M London; B J Everitt; T W Robbins
Journal:  Neuropsychopharmacology       Date:  2000-08       Impact factor: 7.853

View more
  2 in total

1.  Cocaine-specific speed-accuracy trade-off during anti-saccade testing differentiates patients with cocaine use disorder who achieve initial abstinence during treatment.

Authors:  Constanza de Dios; Robert Suchting; Heather E Webber; Jin H Yoon; Luba Yammine; Jessica Vincent; Michael F Weaver; Angela L Stotts; Joy M Schmitz; Scott D Lane
Journal:  J Psychopharmacol       Date:  2021-02-14       Impact factor: 4.153

Review 2.  Mind-Body Approaches to Prevention and Intervention for Alcohol and Other Drug Use/Abuse in Young Adults.

Authors:  Crystal L Park; Beth S Russell; Michael Fendrich
Journal:  Medicines (Basel)       Date:  2018-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.